论文部分内容阅读
目的:评价蒙药清肺润泽丸联合化疗治疗初治和复治继发型肺结核临床疗效,探讨该药对抗结核药物增效、增敏,促进空洞闭合、痰菌转阴、改善症状等作用。方法:采用随机、单盲、平行对照的研究方法,将初治和复治继发型肺结核患者分为试验组和对照组,试验组初治采用前两个月强化期用乙胺丁醇、异烟肼、利福平及吡嗪酰胺,每日1次;后四个月用异烟肼及利福平,每日1次(2HRZE/4HR)加清肺润泽丸(10g/日)和复治采用前两个月强化期用链霉素、乙胺丁醇、异烟肼、利福平及吡嗪酰胺,每日1次;第三个月用乙胺丁醇、异烟肼、利福平及吡嗪酰胺,每日1次;后五个月巩固期用异烟肼、利福平及链霉素,每日1次(2SHRZE/1HRZE/5HRE)加清肺润泽丸(10g/日),对照组采用上述标准化疗方案。肺部病灶吸收率,痰菌转阴率,病症显效率为观察指标。结果:初治患者治疗第1个月、第2个月试验组肺部病灶吸收的患者比例高于对照组,第3~6个月肺部病灶明显吸收的患者比例试验组优于对照组,试验组治疗后肺部病灶吸收率明显降低,与对照组比较有统计学意义(P<0.05);复治患者治疗后第4~8个月试验组肺部病灶明显吸收与吸收的患者比例高于对照组,差异有统计学意义(P<0.05)。试验组治疗第3个月痰菌转阴率达到100%高于对照组,有显著性差异(P<0.05)。试验组改善病症较快,在治疗后第2个月各种病症明显好转,痊愈率试验组优于对照组,有显著性差异(P<0.05)。结论:清肺润泽丸联合化疗治疗初治和复治继发型肺结核临床疗效显著,对化疗药具有增效、增敏作用。
OBJECTIVE: To evaluate the clinical efficacy of Mongolian medicine Qingfei Runze Pill combined with chemotherapy in the treatment of primary and secondary retreatment of pulmonary tuberculosis, and to explore the effects of the drug on antituberculosis drug efficacy, sensitization, empty cavity closure, sputum negative conversion and improvement of symptoms. Methods: A randomized, single-blind, parallel-controlled study was used to divide the patients with newly diagnosed and retreatment secondary pulmonary tuberculosis into experimental group and control group. The experimental group was treated with ethambutol Hydrazide, rifampicin and pyrazinamide once daily; after four months with isoniazid and rifampicin, once daily (2HRZE / 4HR) plus Qingrun Runze pill (10g / day) and complex Treatment with streptomycin, ethambutol, isoniazid, rifampicin and pyrazinamide fortified period of the first two months, once daily; the third month with ethambutol, isoniazid, Lee Fuping and pyrazinamide once daily; after five months of consolidation with isoniazid, rifampicin and streptomycin, once daily (2SHRZE / 1HRZE / 5HRE) plus Qingfei Runze pill (10g / Day), the control group using the standard chemotherapy. Absorption rate of lung lesions, sputum negative rate, disease efficiency was observed indicators. Results: The proportion of patients in the first month and the second month after treatment in the experimental group was higher than that in the control group, and the proportion of patients in the pulmonary tissue in the third and sixth months was significantly better than that in the control group The absorption rate of lung lesions in the experimental group was significantly lower than that in the control group (P <0.05), and the proportion of patients with lung lesions obviously absorbed and absorbed in the experimental group from the 4th to 8th month after treatment was high In the control group, the difference was statistically significant (P <0.05). In the third month of treatment, the rate of negative conversion of sputum was 100% higher than that of the control group (P <0.05). The experimental group to improve the disease faster, in the first 2 months after treatment, a significant improvement in various symptoms, the cure rate of the experimental group was better than the control group, a significant difference (P <0.05). Conclusion: Qingfei Runze Pill combined with chemotherapy has significant clinical effect on primary and secondary retreatment secondary pulmonary tuberculosis and has synergistic and sensitizing effects on chemotherapeutic drugs.